{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-325991","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.250629+00:00","generated_at":"2026-06-28T10:10:09.777071+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nuvation Bio Q3 2021 net loss $22.0M; cash $791.8M; NUV-422 enrollment ongoing","bullets":["Net loss of $22.0M ($0.11 per share) vs $11.0M ($0.12) in Q3 2020.","R&D expenses $17.1M, up from $8.6M; G&A $5.7M, up from $2.9M.","Cash, equivalents and marketable securities $791.8M as of Sept 30, 2021.","Enrollment ongoing in Phase 1/2 study of NUV-422; top-line data expected 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-325991","json":"https://secwatch.observer/filing/0001193125-21-325991.json","markdown":"https://secwatch.observer/filing/0001193125-21-325991.md","text":"https://secwatch.observer/filing/0001193125-21-325991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312521325991/0001193125-21-325991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312521325991/d439428d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:10:09.777071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}